Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pramipexole
Drug ID BADD_D01817
Description Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) [A176867]. It was first approved by the FDA in 1997 [L5882]. Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of disability in patients [A176855], leading to increased difficulty in performing activities of daily living due to symptoms that progress over time [A176858]. The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016 [A176861]. This increase may be attributed to an aging population along with other contributing factors [A176861]. In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (RLS) [A176873]. RLS is a sleep-related disorder characterized by unpleasant sensations in the lower extremities, often accompanied by an uncontrollable urge to move the legs [A176876].
Indications and Usage This drug is indicated for the symptomatic treatment of Parkinson’s disease [FDA label]. This drug can be administered as monotherapy or in conjunction with levodopa. It is also indicated for symptomatic treatment of moderate to severe primary Restless Legs Syndrome (RLS) [FDA label].
Marketing Status approved; investigational
ATC Code N04BC05
DrugBank ID DB00413
KEGG ID D05575
MeSH ID D000077487
PubChem ID 119570
TTD Drug ID D0G8NN
NDC Product Code 31722-910; 31722-906; 10370-305; 31722-909; 31722-911; 31722-907; 31722-908; 10370-253
UNII 83619PEU5T
Synonyms Pramipexole | 4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazole-diamine | Pramipexol | 2-Amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole | Dexpramipexole | Pramipexol, (R)-isomer | Mirapex | Pramipexol Dihydrobromide, (+-)-isomer | Pramipexol Dihydrochloride, (S)-isomer | Pramipexole Dihydrochloride Anhydrous | Sifrol | SND 919CL2x | SND919CL2x | SND-919CL2x | SND-919 | SND 919 | KNS 760704 | KNS760704 | KNS-760704 | Pramipexol, (+-)-isomer | Pramipexole Dihydrochloride | Pramipexole Hydrochloride Monohydrate | 2-Amino-6-propylaminotetrahydrobenzothiazole | 2 Amino 6 propylaminotetrahydrobenzothiazole | 6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate
Chemical Information
Molecular Formula C10H17N3S
CAS Registry Number 104632-26-0
SMILES CCCNC1CCC2=C(C1)SC(=N2)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.000351%Not Available
Intervertebral disc protrusion15.10.01.004--Not Available
Deep vein thrombosis24.01.02.003--Not Available
Respiratory tract congestion22.02.07.003--Not Available
Musculoskeletal stiffness15.03.05.0270.000431%Not Available
Delusional disorder, persecutory type19.03.03.001--Not Available
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.0010.000558%Not Available
Dacryostenosis acquired06.06.04.003--Not Available
Depressive symptom19.15.02.0030.000319%Not Available
Affect lability19.04.01.001--Not Available
Skin burning sensation23.03.03.021; 17.02.06.009--Not Available
Dysphemia19.19.03.005; 17.02.08.0100.000351%Not Available
Foetal death18.01.02.003; 08.04.01.0110.000239%
Parkinsonian gait08.01.02.005; 17.01.05.0050.000239%Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.000399%
Major depression19.15.01.0030.000319%Not Available
Dysgraphia17.02.03.0060.000319%Not Available
Lung neoplasm malignant16.19.02.001; 22.08.01.001--Not Available
Nuchal rigidity15.05.04.005; 17.05.02.006--Not Available
Vasodilation procedure25.03.01.001--Not Available
Restless legs syndrome17.02.07.008; 15.05.03.0120.007209%Not Available
Disturbance in sexual arousal19.08.04.0030.000351%Not Available
Angiopathy24.03.02.007--Not Available
Intervertebral discitis15.02.05.002; 12.02.13.001; 11.01.01.002--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Prostate cancer21.04.02.002; 16.25.01.001--Not Available
Freezing phenomenon17.01.05.0060.001180%Not Available
Abdominal neoplasm07.21.04.001; 16.16.02.002--Not Available
Cardiac disorder02.11.01.0030.000590%Not Available
Embolism24.01.01.009--
The 20th Page    First    Pre   20 21 22 23    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene